Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 550

1.

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial.

Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V; CREDENCE study investigators.

Circulation. 2019 Jul 11. doi: 10.1161/CIRCULATIONAHA.119.042007. [Epub ahead of print]

PMID:
31291786
2.

Long-term efficacy and safety of combined insulin and GLP-1 therapy: evidence from the LEADER trial.

Tack CJ, Jacob S, Desouza C, Bain SC, Buse JB, Nauck MA, Petrie JR, Poulter NR, Pratley RE, Stegmann HVBK, Bosch-Traberg H, Startseva E, Zinman B; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Diabetes Obes Metab. 2019 Jul 7. doi: 10.1111/dom.13826. [Epub ahead of print]

PMID:
31282028
3.

Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial.

Cooper ME, Inzucchi SE, Zinman B, Hantel S, von Eynatten M, Wanner C, Koitka-Weber A.

Am J Kidney Dis. 2019 Jun 26. pii: S0272-6386(19)30735-8. doi: 10.1053/j.ajkd.2019.03.432. [Epub ahead of print] No abstract available.

PMID:
31255334
4.

Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.

Goldenberg RM, Gilbert JD, Hramiak IM, Woo VC, Zinman B.

Diabetes Obes Metab. 2019 Jun 10. doi: 10.1111/dom.13811. [Epub ahead of print] Review.

PMID:
31183975
5.

Intermittent Intensive Insulin Therapy for Type 2 Diabetes: Effects on Hypoglycemia, Weight Gain and Quality of Life Over 2 Years.

Emery A, Ye C, Choi H, Kramer CK, Zinman B, Retnakaran R.

Endocr Pract. 2019 Jun 6. doi: 10.4158/EP-2019-0111. [Epub ahead of print]

PMID:
31170361
6.

Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.

Butler J, Zannad F, Fitchett D, Zinman B, Koitka-Weber A, von Eynatten M, Zwiener I, George J, Brueckmann M, Cheung AK, Wanner C.

Circ Heart Fail. 2019 Jun;12(6):e005875. doi: 10.1161/CIRCHEARTFAILURE.118.005875. Epub 2019 Jun 5.

PMID:
31163986
7.

Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.

Mayer GJ, Wanner C, Weir MR, Inzucchi SE, Koitka-Weber A, Hantel S, von Eynatten M, Zinman B, Cherney DZI.

Kidney Int. 2019 Mar 21. pii: S0085-2538(19)30317-5. doi: 10.1016/j.kint.2019.02.033. [Epub ahead of print]

PMID:
31142441
8.

Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes: The DCCT/EDIC Experience.

Molitch ME, Gao X, Bebu I, de Boer IH, Lachin J, Paterson A, Perkins B, Saenger AK, Steffes M, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group.

Clin J Am Soc Nephrol. 2019 Jun 7;14(6):854-861. doi: 10.2215/CJN.14831218. Epub 2019 May 23.

PMID:
31123181
9.

Oxidative stress and endothelial dysfunction are associated with reduced cognition in type 2 diabetes.

Groeneveld ON, van den Berg E, Johansen OE, Schnaidt S, Hermansson K, Zinman B, Espeland MA, Biessels GJ.

Diab Vasc Dis Res. 2019 May 9:1479164119848093. doi: 10.1177/1479164119848093. [Epub ahead of print]

PMID:
31068001
10.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.

PMID:
30990260
11.

Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).

Pollock RF, Heller S, Pieber TR, Woo V, Gundgaard J, Hallén N, Luckevich M, Tutkunkardas D, Zinman B; DEVOTE Study Group.

Diabetes Obes Metab. 2019 Jul;21(7):1706-1714. doi: 10.1111/dom.13730. Epub 2019 Apr 14.

PMID:
30924579
12.

Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes.

Verma S, Wanner C, Zwiener I, Ofstad AP, George JT, Fitchett D, Zinman B; EMPA-REG OUTCOME Investigators.

J Am Coll Cardiol. 2019 Jun 4;73(21):2780-2782. doi: 10.1016/j.jacc.2019.03.002. Epub 2019 Mar 15. No abstract available.

PMID:
30885684
13.

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.

Savarese G, Sattar N, Januzzi J, Verma S, Lund LH, Fitchett D, Zeller C, George JT, Brueckmann M, Ofstad AP, Inzucchi SE, Wanner C, Zinman B, Butler J.

Circulation. 2019 Mar 12;139(11):1458-1460. doi: 10.1161/CIRCULATIONAHA.118.038339. No abstract available.

PMID:
30855996
14.

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.

Verma S, Bain SC, Monk Fries T, Mazer CD, Nauck MA, Pratley RE, Rasmussen S, Saevereid HA, Zinman B, Buse JB.

Diabetes Obes Metab. 2019 Jul;21(7):1745-1751. doi: 10.1111/dom.13698. Epub 2019 Apr 2.

PMID:
30851070
15.

Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).

Pratley RE, Emerson SS, Franek E, Gilbert MP, Marso SP, McGuire DK, Pieber TR, Zinman B, Hansen CT, Hansen MV, Mark T, Moses AC, Buse JB; DEVOTE Study Group.

Diabetes Obes Metab. 2019 Jul;21(7):1625-1633. doi: 10.1111/dom.13699. Epub 2019 Apr 15.

PMID:
30850995
16.

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.

Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, Thrasher J, Woo V, Philis-Tsimikas A.

Lancet Diabetes Endocrinol. 2019 May;7(5):356-367. doi: 10.1016/S2213-8587(19)30066-X. Epub 2019 Mar 1. Erratum in: Lancet Diabetes Endocrinol. 2019 Mar 11;:. Lancet Diabetes Endocrinol. 2019 Jul 1;:.

PMID:
30833170
17.

HbA1c, Insulin Resistance, and β-Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy.

Janssen J, van den Berg E, Zinman B, Espeland MA, Geijselaers SLC, Mattheus M, Johansen OE, Biessels GJ.

Diabetes Care. 2019 Jan;42(1):e1-e3. doi: 10.2337/DC18-0914. No abstract available.

PMID:
30811335
18.

Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).

Brown-Frandsen K, Emerson SS, McGuire DK, Pieber TR, Poulter NR, Pratley RE, Zinman B, Ranthe MF, Grøn R, Lange M, Moses AC, Örsy P, Buse JB; DEVOTE Study Group.

Diabetes Obes Metab. 2019 Jun;21(6):1437-1444. doi: 10.1111/dom.13677. Epub 2019 Apr 1.

19.

Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial.

Inzucchi SE, Wanner C, Hehnke U, Zwiener I, Kaspers S, Clark D, George JT, Zinman B.

Diabetes Care. 2019 Apr;42(4):e53-e55. doi: 10.2337/dc18-1355. Epub 2019 Jan 31. No abstract available.

PMID:
30705060
20.

Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial.

Verma S, Mazer CD, Bhatt DL, Raj SR, Yan AT, Verma A, Ferrannini E, Simons G, Lee J, Zinman B, George JT, Fitchett D.

Diabetes Care. 2019 Mar;42(3):e42-e44. doi: 10.2337/dc18-1959. Epub 2019 Jan 23. No abstract available.

PMID:
30674547
21.

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.

Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman B.

Circulation. 2019 Mar 12;139(11):1384-1395. doi: 10.1161/CIRCULATIONAHA.118.037778.

22.

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.

McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N; CARMELINA Investigators.

Circulation. 2019 Jan 15;139(3):351-361. doi: 10.1161/CIRCULATIONAHA.118.038352.

PMID:
30586723
23.

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.

Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Pratley RE, Zinman B, Ørsted DD, Monk Fries T, Rasmussen S, Marso SP.

Circulation. 2018 Dec 18;138(25):2884-2894. doi: 10.1161/CIRCULATIONAHA.118.034516.

PMID:
30566004
24.

Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes.

Nunez Lopez YO, Retnakaran R, Zinman B, Pratley RE, Seyhan AA.

Mol Metab. 2019 Feb;20:63-78. doi: 10.1016/j.molmet.2018.11.003. Epub 2018 Nov 16.

25.

HbA1c, Insulin Resistance, and β-Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy.

Janssen J, van den Berg E, Zinman B, Espeland MA, Geijselaers SLC, Mattheus M, Johansen OE, Biessels GJ.

Diabetes Care. 2018 Nov 19. pii: dc180914. doi: 10.2337/dc18-0914. [Epub ahead of print] No abstract available.

PMID:
30455337
26.

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators.

JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269.

27.

Liraglutide and Glycaemic Outcomes in the LEADER Trial.

Zinman B, Nauck MA, Bosch-Traberg H, Frimer-Larsen H, Ørsted DD, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Diabetes Ther. 2018 Dec;9(6):2383-2392. doi: 10.1007/s13300-018-0524-z. Epub 2018 Nov 3.

28.

Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.

DeVries JH, Bailey TS, Bhargava A, Gerety G, Gumprecht J, Heller S, Lane W, Wysham CH, Zinman B, Bak BA, Hachmann-Nielsen E, Philis-Tsimikas A.

Diabetes Obes Metab. 2019 Mar;21(3):622-630. doi: 10.1111/dom.13565. Epub 2018 Nov 26.

29.

Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".

Wanner C, von Eynatten M, Zinman B.

Circulation. 2018 Aug 21;138(8):850-851. doi: 10.1161/CIRCULATIONAHA.118.035881. No abstract available.

PMID:
30359123
30.

Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.

Inzucchi SE, Kosiborod M, Fitchett D, Wanner C, Hehnke U, Kaspers S, George JT, Zinman B.

Circulation. 2018 Oct 23;138(17):1904-1907. doi: 10.1161/CIRCULATIONAHA.118.035759. No abstract available.

PMID:
30354665
31.

Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.

Verma S, Leiter LA, Mazer CD, Bain SC, Buse J, Marso S, Nauck M, Zinman B, Bosch-Traberg H, Rasmussen S, Michelsen MM, Bhatt DL.

Circulation. 2018 Oct 9;138(15):1605-1607. doi: 10.1161/CIRCULATIONAHA.118.036862. No abstract available.

PMID:
30354517
32.

Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease.

Claggett B, Lachin JM, Hantel S, Fitchett D, Inzucchi SE, Woerle HJ, George JT, Zinman B.

Circulation. 2018 Oct 9;138(15):1599-1601. doi: 10.1161/CIRCULATIONAHA.118.033810. No abstract available.

PMID:
30354516
33.

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.

Wanner C, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, Hantel S, Woerle HJ, Broedl UC, von Eynatten M, Groop PH; EMPA-REG OUTCOME Investigators.

J Am Soc Nephrol. 2018 Nov;29(11):2755-2769. doi: 10.1681/ASN.2018010103. Epub 2018 Oct 12.

PMID:
30314978
34.

Rising plasminogen activator inhibitor-1 and hypoadiponectinemia characterize the cardiometabolic biomarker profile of women with recent gestational diabetes.

Mehmood S, Ye C, Connelly PW, Hanley AJ, Zinman B, Retnakaran R.

Cardiovasc Diabetol. 2018 Oct 9;17(1):133. doi: 10.1186/s12933-018-0776-y.

35.

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.

Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, Zinman B, Skyler JS, George J, Soleymanlou N, Perkins BA.

Diabetes Care. 2018 Dec;41(12):2560-2569. doi: 10.2337/dc18-1749. Epub 2018 Oct 4.

PMID:
30287422
36.

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes.

Kramer CK, Zinman B.

Annu Rev Med. 2019 Jan 27;70:323-334. doi: 10.1146/annurev-med-042017-094221. Epub 2018 Sep 26.

PMID:
30256723
37.

Hepatic fat and glucose tolerance in women with recent gestational diabetes.

Mehmood S, Margolis M, Ye C, Maple-Brown L, Hanley AJ, Connelly PW, Sermer M, Zinman B, Retnakaran R.

BMJ Open Diabetes Res Care. 2018 Sep 8;6(1):e000549. doi: 10.1136/bmjdrc-2018-000549. eCollection 2018.

38.

Impact of daily incremental change in environmental temperature on beta cell function and the risk of gestational diabetes in pregnant women.

Retnakaran R, Ye C, Kramer CK, Hanley AJ, Connelly PW, Sermer M, Zinman B.

Diabetologia. 2018 Dec;61(12):2633-2642. doi: 10.1007/s00125-018-4710-3. Epub 2018 Aug 15.

PMID:
30112689
39.

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.

Sattar N, Fitchett D, Hantel S, George JT, Zinman B.

Diabetologia. 2018 Oct;61(10):2155-2163. doi: 10.1007/s00125-018-4702-3. Epub 2018 Jul 31.

40.

Clusters of fatty acids in the serum triacylglyceride fraction associate with the disorders of type 2 diabetes.

Johnston LW, Liu Z, Retnakaran R, Zinman B, Giacca A, Harris SB, Bazinet RP, Hanley AJ.

J Lipid Res. 2018 Sep;59(9):1751-1762. doi: 10.1194/jlr.P084970. Epub 2018 Jul 9.

PMID:
29986954
41.

Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience.

Zinman B, Marso SP, Christiansen E, Calanna S, Rasmussen S, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Diabetes Care. 2018 Aug;41(8):1783-1791. doi: 10.2337/dc17-2677. Epub 2018 Jun 14.

PMID:
29903847
42.

Changes Over Time in Hepatic Markers Predict Changes in Insulin Sensitivity, β-Cell Function, and Glycemia.

Pinnaduwage L, Ye C, Hanley AJ, Connelly PW, Sermer M, Zinman B, Retnakaran R.

J Clin Endocrinol Metab. 2018 Jul 1;103(7):2651-2659. doi: 10.1210/jc.2018-00306.

PMID:
29897453
43.

Biomarkers of vascular injury and endothelial dysfunction after recent glucose intolerance in pregnancy.

Bajaj HS, Ye C, Hanley AJ, Sermer M, Zinman B, Retnakaran R.

Diab Vasc Dis Res. 2018 Sep;15(5):449-457. doi: 10.1177/1479164118779924. Epub 2018 Jun 5.

PMID:
29871496
44.

A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks.

Riddle MC, Gerstein HC, Holman RR, Inzucchi SE, Zinman B, Zoungas S, Cefalu WT.

Diabetes Care. 2018 Jun;41(6):1121-1124. doi: 10.2337/dci18-0018. No abstract available.

PMID:
29784695
45.

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.

Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B.

Diabetologia. 2018 Aug;61(8):1712-1723. doi: 10.1007/s00125-018-4644-9. Epub 2018 May 19.

46.

Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.

Verma S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Marso SP, Nauck MA, Poulter NR, Pratley RE, Zinman B, Michelsen MM, Monk Fries T, Rasmussen S, Leiter LA; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Circulation. 2018 May 15;137(20):2179-2183. doi: 10.1161/CIRCULATIONAHA.118.033898. No abstract available.

47.

Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.

Zinman B, Inzucchi SE, Wanner C, Hehnke U, George JT, Johansen OE, Fitchett D; EMPA-REG OUTCOME® investigators.

Diabetologia. 2018 Jul;61(7):1522-1527. doi: 10.1007/s00125-018-4630-2. Epub 2018 Apr 30.

PMID:
29713728
48.

Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms.

Bajaj HS, Zinman B.

Physiology (Bethesda). 2018 May 1;33(3):197-210. doi: 10.1152/physiol.00004.2018. Review.

49.

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.

Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK; CARMELINA® investigators.

Cardiovasc Diabetol. 2018 Mar 14;17(1):39. doi: 10.1186/s12933-018-0682-3.

50.

Effect of short-term intensive insulin therapy on the incretin response in early type 2 diabetes.

Choi H, Kramer CK, Zinman B, W Connelly P, Retnakaran R.

Diabetes Metab. 2019 Apr;45(2):197-200. doi: 10.1016/j.diabet.2018.01.003. Epub 2018 Jan 11.

PMID:
29395808

Supplemental Content

Loading ...
Support Center